Clinical trials: Pre-emptive Pharmacogenomics
Pre-emptive Pharmacogenomics
Implementation of Pre-emptive Pharmacogenomics Testing in Singapore-based Private Hospital Institutions (IMPT Study)
In collaboration with Raffles Medical Group, we will be recruiting 500 patients and following them for the next 3-12 months to see whether pharmacogenomics information provided in the Raffles' Electronic Health Records (EHR) will…
- Trial name
- NCT05504135
- Testing
- Pharmacogenomics Testing
- Where
- Singapore
- Volunteers
- 222 people
- Sponsor
- Nalagenetics Pte Ltd
Inflammatory Bowel Diseases, Ulcerative Colitis
Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a common disease in Canada, leading to significant morbidity as a result of remitting and relapsing intestinal inflammation.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- INHERIT (NCT04109300)
- Testing
- HLADQA1*05A>G screening, Standard of Care
- Where
- Canada
- Volunteers
- 162 people
- Sponsor
- Western University, Canada
Pharmacogenomic Drug Interaction
PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)
It is known that individuals respond differently to the same medicine with some people benefitting, some experiencing no effect and others suffering side-effects or even coming to harm.
- Trial name
- PHOENIX (NCT06907784)
- Testing
- Pharmacogenomic testing
- Where
- 5 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- NHS Greater Glasgow and Clyde